Paul Tudor Jones Affimed N.V. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$1.96 - $3.32 $27,690 - $46,904
14,128 New
14,128 $29,000
Q2 2022

Aug 15, 2022
SELL
$2.27 - $4.86 $33,353 - $71,407
-14,693 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$3.69 - $5.65 $54,217 - $83,015
14,693 New
14,693 $64,000
Q4 2021

Feb 14, 2022
SELL
$5.37 - $7.07 $106,100 - $139,689
-19,758 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$5.54 - $7.51 $109,459 - $148,382
19,758 New
19,758 $122,000

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email